Stoke Therapeutics, Inc. (NASDAQ:STOK) Major Shareholder Sells $41,760,000.00 in Stock

Stoke Therapeutics, Inc. (NASDAQ:STOK) major shareholder Skorpios Trust sold 3,600,000 shares of the company’s stock in a transaction dated Wednesday, April 17th. The shares were sold at an average price of $11.60, for a total transaction of $41,760,000.00. Following the transaction, the insider now owns 10,843,681 shares in the company, valued at $125,786,699.60. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Stoke Therapeutics Stock Performance

STOK stock traded down $0.07 during mid-day trading on Thursday, hitting $11.65. 1,059,325 shares of the company were exchanged, compared to its average volume of 971,695. The firm has a market cap of $539.40 million, a P/E ratio of -5.01 and a beta of 0.77. The firm’s 50 day simple moving average is $8.47 and its 200 day simple moving average is $5.89. Stoke Therapeutics, Inc. has a 1-year low of $3.35 and a 1-year high of $16.40.

Stoke Therapeutics (NASDAQ:STOK) last announced its earnings results on Monday, March 25th. The company reported ($0.60) EPS for the quarter, topping the consensus estimate of ($0.62) by $0.02. The company had revenue of $2.80 million for the quarter, compared to analyst estimates of $3.70 million. On average, equities research analysts predict that Stoke Therapeutics, Inc. will post -2.28 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on STOK. Needham & Company LLC restated a “buy” rating and set a $22.00 target price on shares of Stoke Therapeutics in a research report on Thursday, April 11th. Canaccord Genuity Group increased their price target on shares of Stoke Therapeutics from $18.00 to $21.00 and gave the company a “buy” rating in a research report on Tuesday, March 26th. TD Cowen upgraded shares of Stoke Therapeutics from a “market perform” rating to an “outperform” rating in a research report on Tuesday, March 26th. HC Wainwright reiterated a “buy” rating and issued a $35.00 price target on shares of Stoke Therapeutics in a research report on Tuesday, March 26th. Finally, Wedbush increased their price target on shares of Stoke Therapeutics from $13.00 to $17.00 and gave the company an “outperform” rating in a research report on Tuesday, March 26th. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, Stoke Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $19.63.

Institutional Trading of Stoke Therapeutics

Several hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. raised its holdings in Stoke Therapeutics by 1.1% during the 4th quarter. Vanguard Group Inc. now owns 1,648,502 shares of the company’s stock worth $8,671,000 after buying an additional 17,814 shares during the period. Barclays PLC raised its holdings in Stoke Therapeutics by 365.3% during the 4th quarter. Barclays PLC now owns 39,271 shares of the company’s stock worth $206,000 after buying an additional 30,831 shares during the period. Granahan Investment Management LLC grew its stake in shares of Stoke Therapeutics by 33.7% during the 4th quarter. Granahan Investment Management LLC now owns 1,137,887 shares of the company’s stock worth $5,985,000 after acquiring an additional 286,686 shares in the last quarter. Bridgeway Capital Management LLC bought a new position in shares of Stoke Therapeutics during the 4th quarter worth approximately $90,000. Finally, Birchview Capital LP grew its stake in shares of Stoke Therapeutics by 147.1% during the 4th quarter. Birchview Capital LP now owns 210,000 shares of the company’s stock worth $1,105,000 after acquiring an additional 125,000 shares in the last quarter.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.